NYVRX Mutual Fund

NAV$31.07

Fund Essentials - as of Apr 30, 2026

Net Assets
$55M
Expense Ratio
1.20%
Dividend Yield (Current)
9.52%
Holdings
47
Inception Date
Aug 20, 2003
Fund Family
Davis Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Semi-Annually

Performance

YTD+9.11%
1 Year+25.38%
3 Year+21.97%
5 Year+10.38%
10 Year+12.91%

Asset Allocation

Stocks: 94.96%
Bonds: 4.99%
Other: 0.06%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
COFCapital One Financial5.69%
CTRACoterra Energy Inc5.28%
GOOGL'alphabet Inc., Class 'a''4.97%
USBU.S. Bancorp Com New4.92%
CVSCvs Health Corp4.24%
Top 10 Concentration: 44.68%Report Date: Apr 30, 2026
Download all 47 holdings for NYVRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
9.52%
Frequency
Semi-Annually
Latest Distribution
$3.51
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how NYVRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

NYVRX Mutual Fund Overview

NYVRX Mutual Fund (Davis New York Venture Fund Class R) is managed by Davis Funds with $54.7M in net assets. NYVRX expense ratio is 1.20%, holding 47 positions across sectors including Unknown, Financials, Communication Services. Inception date: 2003-08-20.

NYVRX performance shows a YTD return of 9.11%. The 1-year return is 25.38% and the 5-year return is 10.38%. NYVRX dividend yield stands at 9.52%, paid semi-annually.

NYVRX top holdings include Capital One Financial (5.7%), Coterra Energy Inc (5.3%), 'alphabet Inc., Class 'a'' (5.0%), U.S. Bancorp Com New (4.9%), Cvs Health Corp (4.2%). View all NYVRX holdings, sector breakdown, or dividend history.

NYVRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. NYVRX alternatives are available via the screener, along with tax-loss harvesting opportunities.